Trial Profile
A Phase 1, Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs DS 3078 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc
- 02 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 May 2014 Planned End Date changed from 1 Apr 2015 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 20 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.